Answers are grounded in this paper and cite their sources.
BACKGROUND Transarterial chemoembolization (TACE) alters hepatic perfusion and can potentially impact portal pressure in hepatocellular carcinoma (HCC) patients. Liver stiffness measurements (LSM) and spleen stiffness measurements (SSM) have emerged as promising tools for assessing portal hypertension. However, limited data exist regarding the effects of TACE on LSM and SSM. We hypothesized that TACE may influence short-term LSM and SSM and that baseline stiffness values can effectively identify patients at high risk for postprocedural hepatic decompensation. AIM To evaluate the short-term effects of TACE on stiffness measurements, and assess their baseline values for predicting 6-month hepatic decompensation. METHODS This prospective cohort study enrolled 102 HCC patients undergoing TACE. LSM and SSM measured by elastography at baseline, day 10, and day 30 post-procedure. A linear mixed-effects model was used to account for missing data with time as a fixed effect and participant identification as a random effect. Hepatic decompensation was defined as a composite endpoint of ascites, variceal bleeding, overt hepatic encephalopathy, and severe liver injury. Multiple logistic regression identified independent predictors of 6-month hepatic decompensation. RESULTS The linear mixed-effects model revealed no significant change in LSM and SSM values on days 10 and 30 after TACE compared to baseline. Within 6 months, 19 patients (18.6%) developed hepatic decompensation. Baseline SSM > 54 kilopascals (kPa) predicted hepatic decompensation with an area under the receiver operating characteristic curve of 0.83 [95% confidence interval (CI): 0.72-0.93], sensitivity of 63.2%, specificity of 90.4%. Multivariate analysis identified modified albumin-bilirubin (mALBI) grade ≥ 2B [adjusted odds ratio (aOR) = 7.05, 95%CI: 1.92-25.94, P = 0.003] and baseline SSM > 54 kPa (aOR = 16.52, 95%CI: 4.39-62.19, P < 0.001) as independent predictors of decompensation. CONCLUSION TACE does not significantly affect short-term stiffness measurements. However, baseline SSM can serve as an effective surrogate marker that complements the mALBI grade for stratifying hepatic decompensation risk.
No takes yet. Share an insight, caveat, or question.
Pattarawongpaiboon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: